Acute Ischemic Stroke Diagnosis Market Size and Share

Acute Ischemic Stroke Diagnosis Market (2026 - 2031)
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Acute Ischemic Stroke Diagnosis Market Analysis by Mordor Intelligence

The acute ischemic stroke diagnosis market size is expected to grow from USD 2.36 billion in 2025 to USD 2.53 billion in 2026 and is forecast to reach USD 3.59 billion by 2031 at 7.27% CAGR over 2026-2031. Aging populations, guideline-driven expansion of mechanical thrombectomy time windows, and the steady infusion of artificial intelligence into emergency radiology are lifting procedure volumes and driving software adoption. Computed tomography (CT) remains the dominant front-line modality, yet AI-enabled stroke triage platforms—now cleared by the U.S. Food and Drug Administration—are shifting capital budgets toward subscription software that accelerates large-vessel occlusion routing. Hospitals are prioritizing door-to-needle metrics because Medicare, European payors, and Japanese insurers attach reimbursement bonuses to imaging-guided workflow performance. North America leads revenue because of its broad network of comprehensive stroke centers, while Asia-Pacific shows the fastest growth as national stroke registries in China and India mandate multimodal imaging for suspected large-vessel occlusion.

Key Report Takeaways

  • By diagnostic technology, computed tomography captured 48.55% of 2025 revenue, while AI-enabled stroke decision-support software is projected to expand at 14.25% CAGR through 2031.
  • By AI software function, large-vessel occlusion detection algorithms held 40.53% of AI software revenue in 2025; perfusion mismatch quantification tools are advancing at 16.75% CAGR through 2031.
  • By care setting, emergency departments generated 62.15% of 2025 care-setting revenue, yet mobile stroke units are forecast to climb at 15.82% CAGR as municipalities deploy CT-equipped ambulances.
  • By end user, hospitals accounted for 74.65% of end-user revenue in 2025; ambulatory surgery and diagnostic imaging centers are growing at 12.32% as outpatient facilities add non-contrast CT for rapid hemorrhage exclusion.
  • By geography, North America contributed 36.23% of global revenue in 2025, whereas Asia-Pacific is projected to expand at 11.42% CAGR through 2031.

Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of January 2026.

Segment Analysis

By Diagnostic Technology: CT Dominance Meets AI Disruption

Multimodal CT imaging generated 48.55% of 2025 technology revenue, underscoring its status as the workhorse of the acute ischemic stroke diagnosis market share during hyperacute triage. The acute ischemic stroke diagnosis market size attributed to AI software, though smaller today, is projected to rise fastest because subscription pricing aligns with cash-flow-constrained hospitals. MRI maintains a foothold for posterior fossa strokes and microbleed detection, but its share will erode marginally as photon-counting CT converges on MRI-like resolution with shorter scan times. 

AI decision-support software is set to scale at 14.25% CAGR through 2031 because payors reward time-to-treatment performance and radiologist shortages create demand for automated pre-reads. Early adopters report sensitivity exceeding 94% for large-vessel occlusion, while false positives remain under 8%, metrics that justify per-use fees of USD 50-80. The convergence of CT hardware upgrades with cloud-deployed AI suites positions imaging OEMs and pure-play vendors to compete on workflow speed rather than pixel quality alone.

Acute Ischemic Stroke Diagnosis Market: Market Share by Diagnostic Technology
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Get Detailed Market Forecasts at the Most Granular Levels
Download PDF

By AI Software Function: Perfusion Quantification Gains Ground

Large-vessel occlusion detection held 40.53% of 2025 AI revenue as every stroke center now prioritizes rapid occlusion identification for thrombectomy routing. Perfusion mismatch quantification tools will capture incremental share because late-window thrombectomy protocols depend on tissue viability rather than elapsed time alone. Vendors packaging occlusion detection, perfusion maps, and hemorrhage exclusion into a single dashboard win contracts by simplifying IT integration. Mobile push notifications reduce team activation times; early data show a 23-minute median reduction in door-to-groin puncture when algorithms auto-page neurointerventional teams.

By Care Setting: Mobile Units Emerge as High-Growth Niche

Hospital emergency departments retained 62.15% share in 2025 because they remain the primary entry point for stroke patients. The acute ischemic stroke diagnosis market will still find its largest installed base inside brick-and-mortar hospitals, yet mobile stroke units are scaling fastest at 15.82% CAGR. Municipalities justify capital outlays of USD 1.2-1.5 million per ambulance by demonstrating 30-50 minute time savings that translate into better functional outcomes and lower long-term disability costs.

Acute Ischemic Stroke Diagnosis Market: Market Share by Care Setting
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Get Detailed Market Forecasts at the Most Granular Levels
Download PDF

By End User: Hospitals Retain Dominance, Outpatient Sites Expand

Hospitals controlled 74.65% of end-user revenue in 2025, reflecting their monopoly on emergency imaging and thrombectomy infrastructure. Outpatient imaging centers and ambulatory surgery centers, however, are growing at 12.32% as value-based care models push volume toward lower-cost settings. The acute ischemic stroke diagnosis industry expects outpatient sites to install non-contrast CT primarily for hemorrhage exclusion before transferring eligible patients, capturing professional fees while avoiding the complexity of full stroke care.

Geography Analysis

North America retained 36.23% global share in 2025 because comprehensive stroke centers exceed 200 and reimbursement is tightly linked to imaging-guided quality metrics. The United States Food and Drug Administration has cleared 12 AI stroke algorithms since 2024, supplying hospitals with multiple vendor options that compete on speed, cloud integration, and subscription price. Canada’s provincial telestroke networks have shortened remote transfer times, while Mexico added 18 CT scanners to regional hospitals but still struggles with a neuroradiologist deficit that slows interpretation turnaround. 

The acute ischemic stroke diagnosis market in Asia-Pacific will expand fastest at 11.42% CAGR because China and India are building stroke registries that compel imaging compliance, and private hospital chains are investing heavily in advanced scanners to appeal to medical tourists. China now operates 1,200 stroke centers, a 35% jump since 2022, and ties reimbursement to imaging protocol adherence. India’s 2024-launched cardiovascular and stroke program earmarked USD 145 million for CT procurement and physician training. Japan, already imaging 92% of stroke suspects within 60 minutes, focuses on ultra-high-field MRI to improve microvascular detection in its rapidly aging society. 

Europe generated a significant revenue in 2025 as Germany’s 340 certified stroke units standardized multimodal CT perfusion, and the United Kingdom added GBP 45 million worth of scanners and AI licenses to expand thrombectomy access. France issued CE-Mark approval to eight AI stroke detection platforms in 2024, triggering rapid procurement by public and private hospitals. Middle East and Africa remain nascent but attract targeted investment; the United Arab Emirates installed 14 new CT scanners in 2024, and South Africa’s handful of comprehensive stroke centers are exploring AI to amplify limited neuroradiology capacity. South America is led by Brazil’s private chains, yet public hospitals lag, with median door-to-CT times still above 90 minutes.

Acute Ischemic Stroke Diagnosis Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Get Analysis on Important Geographic Markets
Download PDF

Competitive Landscape

The acute ischemic stroke diagnosis market is moderately concentrated. Imaging OEMs—Siemens Healthineers, GE HealthCare, Philips, and Canon Medical Systems—leverage their installed hardware bases to bundle AI modules, while pure-play vendors Viz.ai, RapidAI, and Aidoc pursue direct contracts and teleradiology partnerships. Siemens’ Syngo.via stroke module is live at more than 800 hospitals, and 62% of those customers purchase the AI add-on, paying USD 35,000-50,000 annually. GE HealthCare integrated Viz LVO into its Revolution CT, documenting door-to-groin puncture reductions of 21 minutes across 14 validation sites. 

White-space innovators focus on portability: NovaSignal’s Lucid robotic ultrasound automates transcranial Doppler in ambulances, and Hyperfine’s USD 50,000 Swoop portable MRI delivers bedside diffusion-weighted images for unstable ICU patients. Patent filings highlight next-generation photon-counting calibration techniques and federated learning architectures that train AI models without centralizing patient data, a privacy-centric design favored under Europe’s AI Act. 

Regulatory clearance speed is a key differentiator; vendors with both FDA 510(k) and CE Mark secure premium pricing and faster hospital uptake, while investigational tools face longer sales cycles and require institutional review board oversight.

Acute Ischemic Stroke Diagnosis Industry Leaders

  1. Fujifilm Holdings Corporation

  2. Koninklijke Philips NV

  3. Siemens Healthcare

  4. GE HealthCare

  5. Canon Medical Systems

  6. *Disclaimer: Major Players sorted in no particular order
Acute Ischemic Stroke Diagnosis Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • January 2026: The Indian Council of Medical Research delivered two mobile stroke units to Assam, equipping them with CT scanners, teleconsultation links, point-of-care labs, and thrombolytic drugs to bring pre-hospital imaging to remote districts.
  • January 2026: LMU University Hospital researchers reported that circulating brain-derived tau (BD-tau) tracks ischemic injury progression, opening avenues for blood-based monitoring after reperfusion therapies.

Table of Contents for Acute Ischemic Stroke Diagnosis Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing AIS incidence in 65-plus population
    • 4.2.2 Wider adoption of multimodal CT & MR imaging protocols
    • 4.2.3 Expanding endovascular-thrombectomy 24-h time-window
    • 4.2.4 National stroke-care quality initiatives & reimbursement incentives
    • 4.2.5 Photon-counting CT & 7 T MRI enabling microvascular stroke detection
    • 4.2.6 Subscription AI-triage bundles tied to teleradiology contracts
  • 4.3 Market Restraints
    • 4.3.1 High capital & maintenance cost of advanced scanners
    • 4.3.2 Shortage of neuroradiologists in emerging markets
    • 4.3.3 Algorithmic-bias concerns slowing AI regulatory clearance
    • 4.3.4 Xenon-CT consumable supply disruptions raising protocol costs
  • 4.4 Regulatory Landscape
  • 4.5 Technological Outlook
  • 4.6 Porter's Five Forces Analysis
    • 4.6.1 Threat of New Entrants
    • 4.6.2 Bargaining Power of Buyers
    • 4.6.3 Bargaining Power of Suppliers
    • 4.6.4 Threat of Substitutes
    • 4.6.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Diagnostic Technology
    • 5.1.1 Computed Tomography (NCCT, CTA, CTP)
    • 5.1.2 Magnetic Resonance Imaging (DWI, SWI, ASL)
    • 5.1.3 Carotid & Trans-cranial Ultrasound
    • 5.1.4 Cerebral Angiography (DSA)
    • 5.1.5 Blood-based Biomarker Tests
    • 5.1.6 AI-enabled Stroke Decision-Support Software
  • 5.2 By AI Software Function
    • 5.2.1 Early-Event Triage & Alerting
    • 5.2.2 Large-Vessel-Occlusion Detection
    • 5.2.3 Perfusion Mismatch Quantification
    • 5.2.4 Hemorrhage Exclusion
  • 5.3 By Care Setting
    • 5.3.1 Emergency Department In-hospital
    • 5.3.2 Mobile Stroke Unit
    • 5.3.3 Telestroke Hub & Spoke
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Diagnostic Imaging Centers
    • 5.4.3 Ambulatory Surgery Centers / Others
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Canon Medical Systems
    • 6.3.2 Ceribell
    • 6.3.3 Esaote SpA
    • 6.3.4 Fujifilm Holdings
    • 6.3.5 GE HealthCare
    • 6.3.6 Hyperfine
    • 6.3.7 Koninklijke Philips N.V.
    • 6.3.8 Medtronic Neurovascular
    • 6.3.9 MicroPort Scientific
    • 6.3.10 MicroVention
    • 6.3.11 Neusoft Medical
    • 6.3.12 Nihon Kohden
    • 6.3.13 NovaSignal
    • 6.3.14 Penumbra Inc.
    • 6.3.15 RapidAI
    • 6.3.16 Siemens Healthineers
    • 6.3.17 Stryker Neurovascular
    • 6.3.18 Viz.ai

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Research Methodology Framework and Report Scope

Market Definitions and Key Coverage

Our study defines the acute ischemic stroke diagnosis market as the annual revenue generated worldwide from imaging systems, ultrasound devices, cerebral angiography suites, and validated blood-based biomarker tests used for first-line or confirmatory detection of an ischemic event within 24 hours of symptom onset. Value is captured at the equipment manufacturer or assay provider list price and excludes therapeutic products, implantable monitoring devices, and post-stroke rehabilitation services.

Scope exclusions, screening tools for hemorrhagic or transient ischemic attack without an ischemic module, are left outside the frame.

Segmentation Overview

  • By Diagnostic Technology
    • Computed Tomography (NCCT, CTA, CTP)
    • Magnetic Resonance Imaging (DWI, SWI, ASL)
    • Carotid & Trans-cranial Ultrasound
    • Cerebral Angiography (DSA)
    • Blood-based Biomarker Tests
    • AI-enabled Stroke Decision-Support Software
  • By AI Software Function
    • Early-Event Triage & Alerting
    • Large-Vessel-Occlusion Detection
    • Perfusion Mismatch Quantification
    • Hemorrhage Exclusion
  • By Care Setting
    • Emergency Department In-hospital
    • Mobile Stroke Unit
    • Telestroke Hub & Spoke
  • By End User
    • Hospitals
    • Diagnostic Imaging Centers
    • Ambulatory Surgery Centers / Others
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Detailed Research Methodology and Data Validation

Primary Research

Several conversations with neurologists, interventional radiologists, stroke center administrators, and procurement managers across North America, Europe, China, India, and Brazil helped validate imaging mix shifts, average scan pricing, and practical adoption rates of AI decision-support modules. Structured surveys with modality vendors and regional distributors filled data gaps around average selling prices and replacement cycles, guiding assumption fine-tuning.

Desk Research

Mordor analysts first mapped the diagnostic pathway through publicly available guidelines from bodies such as the American Heart Association, European Stroke Organization, and Japan Stroke Society. They then paired that clinical flow with equipment shipment and install data released by regulators (US FDA 510(k) summaries, European CE mark databases) and customs codes aggregated by UN Comtrade, OECD health statistics, and national ministries of health. Company 10-Ks, investor decks, and Factiva-archived earnings calls supplied benchmark selling prices and utilization commentary, while D&B Hoovers aided in cross-checking vendor revenue splits. Peer-reviewed articles in journals like Stroke and the Journal of Neuroimaging were referenced for prevalence-to-diagnosis conversion factors. This list is illustrative; many other sources informed data collection and verification.

Market-Sizing & Forecasting

A single-year top-down build starts with country-level ischemic stroke incidence, adjusts for emergency presentation rates, and multiplies by diagnostic pathway penetration to derive procedure volumes, which are then converted to value using weighted average selling prices. Sampled supplier roll-ups and channel checks offer bottom-up reasonableness. Key variables feeding the model include stroke incidence per 100,000 population, CT and MRI installed base, emergency department turnaround targets, payer reimbursement ceilings, and adoption curves for rapid blood biomarker panels. Forecasts through 2030 rely on multivariate regression that links procedure growth to aging population trends, CT/MRI replacement waves, and health expenditure elasticity under three scenario bands reviewed with primary experts. Gaps in granular shipment data are bridged with regional proxy ratios anchored to historical install-base audits.

Data Validation & Update Cycle

Outputs undergo variance checks against third-party hospital utilization datasets and time-series consistency reviews by a senior analyst. Anomalies trigger re-contacts with sources before sign-off. Reports refresh yearly, with interim reruns when regulatory or reimbursement events materially move the baseline.

Why Mordor's Acute Ischemic Stroke Diagnosis Baseline Stands Firm

Published estimates often diverge because firms differ in stroke type coverage, bundle laboratory panels with imaging in varying ways, or apply distinct currency conversion cadences.

Key gap drivers in other publications revolve around broader stroke categories, inclusion of monitoring equipment, or unvetted average price progression, whereas Mordor restricts scope strictly to acute ischemic diagnostic modalities, applies incidence-driven demand pools, and refreshes base data every twelve months.

Benchmark comparison

Market SizeAnonymized sourcePrimary gap driver
USD 2.36 B (2025) Mordor Intelligence-
USD 3.99 B (2025) Global Consultancy ABundles lab assays and metabolic panels beyond acute imaging
USD 4.57 B (2024) Trade Journal BAdds monitoring devices and all stroke categories, not only acute ischemic
USD 3.34 B (2025) Industry Association CCombines ischemic and hemorrhagic diagnostics, uses broad device ASP escalator

The comparison shows that figures swell when wider disease categories or device groups are folded in. By selecting a clinically precise scope, grounding volumes in incidence data, and reconciling price points with field interviews, Mordor Intelligence delivers a balanced, transparent baseline that decision-makers can trace back to clear variables and repeatable steps.

Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What CAGR is projected for the acute ischemic stroke diagnosis market during 2026-2031?

The market is forecast to expand at 7.27% CAGR over 2026-2031.

Which diagnostic technology currently holds the highest revenue share?

Multimodal CT imaging commanded 48.55% of 2025 revenue.

Which AI software function is growing fastest?

Perfusion mismatch quantification tools are advancing at 16.75% CAGR through 2031.

What geography is expected to grow most rapidly?

Asia-Pacific is projected to increase at 11.42% CAGR through 2031.

How fast are mobile stroke units expanding?

Mobile units are forecast to rise at 15.82% CAGR by 2031 as municipalities invest in pre-hospital imaging.

What is the key restraint hampering scanner adoption in emerging markets?

The high capital and maintenance cost of photon-counting CT and 7 T MRI systems limits uptake in resource-constrained hospitals.

Page last updated on: